David Straus

710 total citations
8 papers, 536 citations indexed

About

David Straus is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, David Straus has authored 8 papers receiving a total of 536 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 4 papers in Oncology and 3 papers in Genetics. Recurrent topics in David Straus's work include Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (3 papers) and CNS Lymphoma Diagnosis and Treatment (3 papers). David Straus is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (3 papers) and CNS Lymphoma Diagnosis and Treatment (3 papers). David Straus collaborates with scholars based in United States, France and Hungary. David Straus's co-authors include Daniel A. Filippa, Paul Sherlock, Jerome J. DeCosse, Philip Lieberman, Daniel N. Weingrad, Ariela Noy, Andrew D. Zelenetz, Eric Hedrick, Craig H. Moskowitz and Carol S. Portlock and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

David Straus

8 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Straus United States	6	467	280	154	123	93	8	536
Fred Rosenfelt United States	8	341 0.7×	188 0.7×	195 1.3×	88 0.7×	209 2.2×	15	514
Fergus Jack United Kingdom	6	265 0.6×	158 0.6×	83 0.5×	47 0.4×	52 0.6×	10	347
Rafael Carrión Spain	9	238 0.5×	165 0.6×	64 0.4×	91 0.7×	43 0.5×	20	371
Peter Forsyth United Kingdom	7	152 0.3×	103 0.4×	136 0.9×	50 0.4×	35 0.4×	14	391
Alejandra Zárate‐Osorno United States	13	352 0.8×	258 0.9×	133 0.9×	45 0.4×	81 0.9×	22	544
M. Planker Germany	11	163 0.3×	475 1.7×	68 0.4×	432 3.5×	29 0.3×	16	714
Roberto Freilone Italy	13	420 0.9×	321 1.1×	230 1.5×	70 0.6×	151 1.6×	46	591
Jan Siehl Germany	12	130 0.3×	205 0.7×	44 0.3×	59 0.5×	49 0.5×	28	385
Teresio Motta Italy	8	244 0.5×	283 1.0×	41 0.3×	47 0.4×	54 0.6×	11	394
Donna M. Weber United States	4	110 0.2×	126 0.5×	78 0.5×	72 0.6×	39 0.4×	4	381

Countries citing papers authored by David Straus

Since Specialization

Citations

This map shows the geographic impact of David Straus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Straus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Straus more than expected).

Fields of papers citing papers by David Straus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Straus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Straus. The network helps show where David Straus may publish in the future.

Co-authorship network of co-authors of David Straus

This figure shows the co-authorship network connecting the top 25 collaborators of David Straus. A scholar is included among the top collaborators of David Straus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Straus. David Straus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Gallamini, Andrea, David Straus, Monika Długosz‐Danecka, et al.. (2019). S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3‐YEAR UPDATE OF THE ECHELON‐1 STUDY. HemaSphere. 3(S1). 362–363. 1 indexed citations

Straus, David, Malik E. Juweid, Nathan C. Hall, et al.. (2007). Doxorubicin, Vinblastine and Gemcitabine (AVG), a Novel Regimen Excluding Bleomycin for the Treatment of Early Stage Hodgkin Lymphoma (HL): Results of CALGB 50203.. Blood. 110(11). 214–214. 5 indexed citations

Hamlin, Paul A., Craig H. Moskowitz, David Straus, et al.. (2007). Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL). Journal of Clinical Oncology. 25(18_suppl). 8051–8051. 9 indexed citations

Halaas, Jeffrey L., Craig H. Moskowitz, Steven M. Horwitz, et al.. (2005). R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy. Leukemia & lymphoma. 46(4). 541–547. 31 indexed citations

Straus, David, et al.. (2001). Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma. Leukemia & lymphoma. 42(5). 1015–1022. 52 indexed citations

Moskowitz, Craig H., Joseph R. Bertino, Jill R. Glassman, et al.. (1999). Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 17(12). 3776–3785. 230 indexed citations

Ratner, Lee, David T. Redden, Fayez M. Hamzeh, et al.. (1999). CHEMOTHERAPY FOR HIV-ASSOCIATED NON-HODGKIN LYMPHOMA (HIV-NHL) IN COMBINATION WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS NOT ASSOCIATED WITH EXCESSIVE TOXICITY.. JAIDS Journal of Acquired Immune Deficiency Syndromes. 21(1). A32–A32. 17 indexed citations

Weingrad, Daniel N., Jerome J. DeCosse, Paul Sherlock, et al.. (1982). Primary gastrointestinal lymphoma:A 30-year review. Cancer. 49(6). 1258–1265. 191 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact